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Amphotropic murine leukemia virus (MLV) can replicate in human cells and is a potential contaminant in vector prepara-
tions for human gene transfer studies. We have recently shown that replication of amphotropic MLV in specific human
sarcoma and lymphoma lines is possible in the absence of the viral 75-bp transcription enhancer elements. Here, we have
tested the replication of an amphotropic MLV, MLV-(MOA), and an enhancer-deficient mutant of this virus in human breast
carcinoma-derived cell lines. The proviral expression plasmids use a cytomegalovirus (CMV) promoter for the initial
transcription of virus RNA. We found that all cells analyzed are permissive for replication of MLV-(MOA). Enhancer-deficient
virus is unable to replicate. However, in two lines the replication defect can be rescued by the spontaneous insertion of a
CMV promoter and enhancer into the U3 region. This recombinant virus MLV-(RCMV) replicates with kinetics similar to that
of MLV-(MOA) but is restricted to specific cell lines. The potential formation of RCMV recombinants during MLV vector
preparation must be considered. © 2001 Elsevier Science
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Amphotropic murine leukemia virus was originally iso-
lated from feral mice and found to replicate in cells from
various mammalian species including humans (Hartley
and Rowe, 1976; Rasheed et al., 1976). The env gene of
isolate 4070A (Miller et al., 1985) was subsequently used
for transduction of primate cells with murine leukemia
virus (MLV) vectors (Cone and Mulligan, 1984; Sorge et
al., 1984). Most retroviral vectors in use for human gene
therapy have been derived from the Moloney strain of
murine leukemia virus (Mo-MLV) and frequently use an
amphotropic host range to introduce marker or therapeu-
tic genes (Marcel and Grausz, 1996). Recombinant, rep-
lication-competent amphotropic murine leukemia virus is
a potential contaminant and safety risk in these vector
preparations (Donahue et al., 1992; Otto et al., 1994).
However, very little information is available about the
replication and gene expression of amphotropic MLV in
human cells. The original characterization of these vi-
ruses was done in fibroblasts and sarcoma lines (Hartley
and Rowe, 1976; Rasheed et al., 1976). A more detailed
analysis of amphotropic MLV replication in human cells
revealed extreme differences in the virus production of
different cell types (Cornetta et al., 1993): The highest
titers were found in fibroblasts and endothelial cells and
intermediate titers were associated with hematopoietic
cell lines. HTLV-transformed T cell lines and primary
1 To whom correspondence and reprint requests should be ad-
dressed. Fax: 49-6221-424902. E-mail: f.reuss@dkfz.de.
91tumor infiltrating lymphocytes had a very low to nonde-
tectable titer. For many human cell types it is not known
whether or not they are permissive for amphotropic MLV.
Human epithelial cells have not yet been tested. We
were particularly interested in analyzing amphotropic
MLV replication in human breast epithelial cells, since
transmission of this virus in mice occurs primarily via
mother’s milk (Gardner, 1978).
MLV gene expression requires transcription from the
MLV long terminal repeat (LTR) and is observed in a wide
range of cell types. Mo-MLV transcription in murine cells
is determined by a promoter and two copies of a 75-bp
transcriptional enhancer element in the U3 region of the
viral LTR (Graves et al., 1985). Cellular transcription fac-
tors that interact with the 75-bp repeats of Mo-MLV were
characterized (Coffin et al., 1997). LTRs with a deletion of
both enhancers show a drastically reduced promoter
activity (#0.1%) in reporter gene assays (Hanecak et al.,
1986). As a consequence, Mo-MLV mutants that lack
both 75-bp enhancer elements are replication-deficient
in murine 3T3 fibroblasts (Hanecak et al., 1986). Experi-
mental substitution of enhancers in the ecotropic Mo-
MLV with heterologous elements generated recombinant
virus with novel biological features in rodents (Hanecak
et al., 1988). The formation of amphotropic MLV recom-
binants with heterologous transcription elements in hu-
man cells has not been described yet.
None of the above studies addresses the transcription
mechanisms during replication of amphotropic MLV in
human cells. We have recently demonstrated that am-
photropic MLV replication in specific human sarcoma
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92 REUSS ET AL.and lymphoma cells can occur in the absence of the viral
75-bp enhancer elements (F. U. Reuss, B. Berdel, M.
Ploss, and R. Heber, submitted for publication). To ana-
lyze the effect of the 75-bp MLV enhancers on MLV gene
expression and replication in human epithelial cells, we
have tested the replication capacity of an infectious,
amphotropic murine leukemia virus and a corresponding
enhancer-deficient mutant in a panel of human breast
carcinoma-derived cell lines. Spontaneously arising re-
combinants that rescue the replication defect of enhancer-
deficient virus were characterized.
RESULTS
Generation of an amphotropic Moloney murine
leukemia virus variant and a corresponding enhancer-
deficient mutant
Information about the replication of amphotropic MLV
in human cells is very limited. In murine cells transcrip-
tion and replication of Mo-MLV is determined by two
75-bp transcriptional enhancer elements within the viral
LTR (Hanecak et al., 1986). To characterize the effect of
these enhancers on MLV transcription and replication in
human cells we have generated the amphotropic host
range variant MLV-(MOA) of the infectious Mo-MLV pro-
virus 63-2 (Bacheler and Fan, 1981). Provirus MLV-(MOA)
includes the env gene from the amphotropic MLV strain
4070A (Chattopadhyay et al., 1981) in place of the origi-
nal, ecotropic env gene to extend the virus host range to
human cells (Fig. 1). The corresponding enhancer-defi-
cient mutant MLV-(MOA)DE is characterized by a dele-
tion that extends from position 2357 to 2150 in the U3
region and removes both enhancer copies at positions
2341 to 2257 and 2266 to 2182 (Hanecak et al., 1986).
The initial transcription of viral RNAs in both MLV-(MOA)
and MLV-(MOA)DE is under the control of the cytomeg-
alovirus (CMV) major immediate-early (IE) promoter.
FIG. 1. Provirus structure of Moloney murine leukemia virus, the
amphotropic virus MLV-(MOA), and the enhancer-deficient mutant MLV-
(MOA)DE. Depicted are the LTRs (open boxes) with the U3, R, and U5
regions and the two 75-bp enhancer elements (hatched boxes), the
viral genes (gag-pol, env), the CMV IE promoter/enhancer unit (black
arrowhead), and the deletion that removes the viral enhancers (2357 to
2150). The viral genomic RNA is represented below the proviruses.Transcription initiation occurs precisely at the same po-
sition as in the original MLV LTR (Soneoka et al., 1995)(Fig. 1). Reversion of the enhancer mutant to wildtype
virus by recombination between wildtype and mutant U3
regions of the same provirus, previously found in similar
experiments (Overhauser and Fan, 1985), is not possible.
Replication of amphotropic MLV in human mammary
carcinoma cell lines
To test the influence of the MLV 75-bp enhancer ele-
ments on replication and gene expression of ampho-
tropic MLV in human epithelial cells we transfected the
plasmids pMLV-(MOA) and pMLV-(MOA)DE, containing
an intact amphotropic MLV provirus and a corresponding
enhancer-deficient mutant, respectively, into the human
breast carcinoma-derived cell lines MCF-7, T47D, BT474,
MDA-MB-435S, and ZR-75-1 and the murine, MLV-per-
missive control cell line NIH/3T3. The selected breast
cancer lines are heterogeneous with respect to origin,
genetic background, expression of estrogen receptors,
and other markers (Clarke et al., 1996; Rønnov-Jessen et
al., 1996). The initial transcription of both proviruses from
the CMV promoter results in the production of virions that
infect susceptible cells in the culture. The newly gener-
ated proviruses in these cells have identical U3 regions,
either wildtype or mutant, in both LTRs. Transcription-
and replication-competent virus spreads in the culture
until all susceptible cells are infected and superinfection
resistance is established. Transfected cells were main-
tained in DMEM for a period of 80 days to allow virus
spread. When cultures reached confluence, cells were
trypsinized and diluted into fresh medium. Medium was
harvested and used to determine virus-associated re-
verse-transcriptase (RT) activity as a measure of virus
replication.
We found that the amphotropic virus MLV-(MOA) rep-
licates in all human breast carcinoma-derived cell lines
tested (Fig. 2). The replication kinetics differed between
the individual cell lines. Virus replication was detected
very rapidly in NIH/3T3 control cells (#3 days) and
MCF-7 (’5 days), ZR-75-1 (#8 days), and BT474 (#13
days) cells, but required a longer period in MDA-MB-
435S (’12 days) and T47D (’31 days) cells. The differ-
ences in the replication kinetics are to a large degree
due to differences in the initial transfection efficiencies
between the lines. The infection of MCF-7 and T47D cells
with MLV-(MOA) demonstrates that the differences in the
replication rate constant of the virus are quite modest.
The rate constant in T47D cells is approximately 50% of
the rate constant in MCF-7 cells (data not shown). The RT
activity in the medium of cells transfected with plasmid
pMLV-(MOA) reached levels that were approximately two
orders of magnitude higher than in the corresponding
mock control samples. RT values above 2 3 106 cpm/ml
were not resolved in this experiment.The enhancer-deficient mutant virus MLV-(MOA)DE, in
the same experiment, was unable to replicate in NIH/3T3
93AMPHOTROPIC MURINE LEUKEMIA VIRUSFIG. 2. Replication of amphotropic murine leukemia virus after transfection of proviral expression plasmids. The human breast carcinoma-derived
cell lines MCF-7, ZR-75-1, BT-75, MDA-MB-435S, and T47D and the murine control cell line NIH/3T3 were transfected with plasmids pMLV-(MOA) (open
circles) or pMLV-(MOA)DE (filled circles) or in the absence of plasmid (mock) (open squares). Cells were passaged for a period of 80 days and
reverse-transcriptase activity was determined from the medium.
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2). Similarly, MLV-(MOA)DE replication in the human
T47D, BT474, and MDA-MB-435S cells was not detected.
In contrast, replication of MLV-(MOA)DE was observed in
human MCF-7 and ZR-75-1 carcinoma cells. RT activity
above mock control values is detectable after $18 days
(MCF-7) and $34 days (ZR-75-1). In both cell lines the
appearance of RT activity was delayed relative to MLV-
(MOA) for ’13 days (MCF-7) and ’26 days (ZR-75-1).
Repeated tests in NIH/3T3 and MCF-7 cells both under
these standard conditions and in the presence of estra-
diol or dexamethasone confirmed the above results (data
not shown). As determined in serial dilution experiments,
virus expression in MCF-7 and ZR-75-1 cells transfected
with the enhancer-deficient MLV reached 98 and 57% of
the respective wildtype levels. In summary, we found that
the amphotropic murine leukemia virus MLV-(MOA) rep-
licates in all human breast carcinoma-derived cell lines
tested. The 75-bp enhancer elements in the viral U3
region were required for replication in three of five hu-
man cell lines. Replication in the absence of these en-
hancers was observed in MCF-7 and ZR-75-1 cells, albeit
with a delayed time course. The delayed replication
kinetics can be explained by a residual replication in the
absence of LTR enhancers or alternatively reflects the
selection of mutant virus with additional genetic changes
that compensate for the enhancer defect. To distinguish
between these two possibilities we analyzed the struc-
ture of MLV proviruses in infected MCF-7 and ZR-75-1
cells and compared the replication kinetics of virus har-
vested from these cells.
Replication of enhancer-deficient MLV is restored by
insertion of the CMV IE promoter into the U3 region
To determine the structure of MLV proviruses in MCF-7
and ZR-75-1 cells, we isolated the genomic DNA of
uninfected, MLV-(MOA)-infected, and MLV-(MOA)DE-in-
fected cells after 80 days in culture and characterized the
proviruses in a Southern blot experiment. To confirm the
presence of MLV in infected lines, HindIII-digested DNA
was hybridized to probe 1 representing the pol and env
genes of the virus (Fig. 3A). We found that for both MCF-7
and ZR-75-1 cells, the cultures infected with the intact
MLV-(MOA) and the enhancer-deficient MLV-(MOA)DE
contained comparable numbers of proviruses. The num-
ber of proviral copies per microgram of DNA was lower
in MCF-7 than in ZR-75-1. The size of the HindIII fragment
(2.0 kb) was identical for MLV-(MOA), MLV-(MOA)DE, and
the proviral plasmids, excluding major rearrangements
in this part of the genome during replication. No MLV or
related virus was detected in the parental MCF-7 and
ZR-75-1 lines.
Compensatory changes in the MLV-(MOA)DE viral
LTRs such as insertion or duplication are likely to in-
crease the size of the U3-R region. Reversion of mutantvirus or contamination with MLV-(MOA) would be identi-
fied by an intact U3-R region. To determine the size of the
U3-R region in proviral 39 LTRs, the genomic DNAs de-
scribed above were digested with HindIII and KpnI, hy-
bridized to probe 2 representing the 39 portion of the env
gene, and compared to the proviral expression plasmids
(Fig. 3B). As expected, the parental proviral plasmids
pMLV-(MOA) and pMLV-(MOA)DE yielded 1.4- and 1.2-kb
fragments, respectively. The size difference reflects the
207-bp deletion that removes the two 75-bp enhancer
elements from the LTR in MLV-(MOA)DE. MCF-7 and
FIG. 3. Characterization of MLV proviruses in chronically infected
MCF-7 and ZR-75-1 cells. Genomic Southern blot of DNA from MCF-7
and ZR-75-1 cells transfected with pMLV-(MOA) or pMLV-(MOA)DE
provirus expression plasmids (MOA, DE). Cellular genomic DNA
(MCF-7, ZR-75-1) and control plasmids (MOA, DE) were digested with
HindIII (A), or HindIII 1 KpnI (B and C), separated on an agarose gel.
After Southern transfer the membranes were hybridized with probe 1
(A), probe 2 (B), or probe CMV (C). The approximate size of identified
fragments in kilobases is indicated on the left; the name of the virus is
given on the right side [MOA, DE, recombinant 1 (rec. 1), recombinant
2 (rec. 2)]. A schematic representation of an MLV provirus is shown
below C with the LTRs (open box), U3, R, and U5 regions, genes (gag,
pol, env), restriction sites for HindIII (H) and KpnI (K), and the position
of probes 1 and 2. The CMV probe represents the IE gene promoter
region from position 2521 to 214 (Thomsen et al., 1984).ZR-75-1 cells infected with the intact MLV-(MOA) con-
tained a 1.4-kb fragment characteristic for the intact virus.
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deficient virus MLV-(MOA)DE only a minor proportion of
the proviruses maintained the structure of the parental
provirus. The majority of proviruses were characterized
by U3-R fragments of 1.65 or 1.4 kb, suggesting the
predominance of two recombinant virus populations (re-
combinants 1 and 2). The U3-R region of the minor
recombinant 2 is very similar in size to the corresponding
region of the intact MLV-(MOA).
In previous related experiments, recombination of the
enhancer-deficient 39 LTR with the intact 59 LTR allowed
the reversion of the mutant virus (Overhauser and Fan,
1985). In an analogous fashion, recombination with the
CMV promoter in our provirus expression plasmids may
have altered the U3 region and permitted virus replica-
tion. To test this hypothesis, we used a CMV promoter
probe for the hybridization to HindIII/KpnI-digested DNA
from MCF-7 and ZR-75-1 cells to detect potential CMV
promoter integrations in the provirus (Fig. 3C). The pro-
viral expression plasmids pMLV-(MOA) and pMLV-
(MOA)DE digested with the same enzymes served as
control and generated a 3.3-kb CMV promoter-positive
fragment. None of the cellular DNAs tested contained
detectable amounts of the proviral plasmids used for
transfection. CMV promoter DNA was detected in MCF-7
and ZR-75-1 cells transfected with the enhancer-defi-
cient provirus plasmid pMLV-(MOA)DE but not in mock-
or pMLV-(MOA)-transfected cells. The CMV promoter
was present in two 1.65- and 1.4-kb-sized fragments in
both cell lines. The size of these fragments is identical to
the U3-R region of recombinants 1 and 2 identified
above. These data suggest that the replication capacity
of the enhancer-deficient MLV-(MOA)DE in MCF-7 and
ZR-75-1 cells has been restored by the insertion of the
CMV promoter into the viral U3 region. Contamination
with MLV-(MOA) can be excluded. The newly generated
CMV promoter-recombinant viruses 1 and 2 were named
MLV-(RCMV 1) and (RCMV 2), respectively.
Replication of the recombinant virus MLV-(RCMV) is
restricted to specific human cell lines
To determine the biological characteristics of the MLV-
(RCMV) virus we compared the replication of MLV-(MOA)
and the recombinant virus MLV-(RCMV) in selected cell
lines. MLV-(MOA)- or MLV-(RCMV)-containing culture
medium from infected MCF-7 and ZR-75-1 cells was
used for infection of fresh target cells. Equivalent
amounts of virus, as calculated from the RT activity in the
medium samples, were used to infect NIH/3T3, MDA-
MB-435S, ZR-75-1, and MCF-7 cells. After removal of the
virus inoculum the cells were maintained for a period of
55 days and RT activity in the medium was determined
as a measure of virus replication (Fig. 4).As seen before, MLV-(MOA) replicated in all the cell
lines tested. By contrast, we found that MLV-(RCMV)replicated in MCF-7 and ZR-75-1 cells, but did not in
NIH/3T3 and MDA-MB-435S cells. The replication kinet-
ics of this virus was similar to that of MLV-(MOA) in
ZR-75-1 cells and moderately faster than MLV-(MOA) in
MCF-7 cells. MCF-7 cells were permissive for MLV-
(RCMV) originating from ZR-75-1 cells and vice versa. We
conclude that MLV-(RCMV) is an infectious virus that can
be transmitted via filtered medium. The lack of replica-
tion in NIH/3T3 and MDA-MB-435S cells distinguishes
this virus from MLV-(MOA). The replication kinetics of
both viruses is similar in cells permissive for both vi-
ruses, but MLV-(RCMV) is restricted to specific cell lines.
The structure of the MLV-(RCMV) U3 region
To precisely determine the structure of the hybrid
MLV/CMV-U3 region in the MLV-(RCMV) viruses, we iso-
lated virus RNA from the culture supernatants of MLV-
(MOA)- or MLV-(MOA)DE-infected MCF-7 cells. The
cDNA generated from these RNAs was used in a PCR to
amplify the viral U3-R region. Due to the presence of
slightly divergent R regions at the 59 and 39 terminis of
the initial viral transcript we used either primer FS 3 (for
the MLV R region) or primer HR 2 (for the MSV R region)
in combination with the U3 primer FS 1. In a parallel PCR
the corresponding region from the proviral expression
plasmids was amplified as control. The PCR products
were resolved on a PAA gel to detect even small size
differences between the U3 regions from the transfected
plasmid and the resulting virus (Fig. 5).
We found that virus from the culture medium of MLV-
(MOA)-infected MCF-7 cells contained a 492-bp U3-R
fragment characteristic for the intact MLV-(MOA) (Fig. 5).
In medium from a MCF-7 culture infected with MLV-
(RCMV) we did not detect the 286-bp fragment that is
indicative of the enhancer-deficient MLV-(MOA)DE, but
found a major 780-bp fragment and a minor 520-bp
fragment (Fig. 5). No viral RNA was detected in mock-
infected, RT-negative MCF-7 cultures. These results ex-
clude contamination with MLV-(MOA) and confirm the
data obtained in the Southern blots. The PCR products
obtained were cloned into a plasmid vector. Two inde-
pendent plasmids with a 780-bp insert and one plasmid
with a 520-bp fragment were selected for sequence
analysis (Fig. 6). In all three clones a CMV IE promoter
and enhancer unit is found integrated between the en-
hancer-deficient U3 and the R region. The CMV compo-
nents correspond to position 2458 to 21 in recombinant
RCMV 1 and 2238 to 21 in recombinant RCMV 2 of the
IE gene promoter and include the TATA-box plus different
portions of the upstream regulatory/enhancer region
(Thomsen et al., 1984). The replication properties of MLV-
(RCMV1) and MLV-(RCMV2) were separately analyzed by
ligation of RCMV1, RCMV2, and MOA LTRs into a provirus
with a defective 39 LTR. After transfection in MCF-7 cells,
the viral replication rate constants of the recombinants
FIG. 4. Infection studies with amphotropic virus MLV-(MOA) and the CMV promoter recombinant virus MLV-(RCMV). Cell lines NIH/3T3,
MDA-MB-435S, MCF-7, and ZR-75-1 were infected with equivalent amounts of MLV-(MOA) (open circles) or MLV-(RCMV) virus (filled circles) harvested
from either MCF-7 or ZR-75-1 cells and cultured for 55 days. Uninfected control cultures are represented by open squares. Reverse-transcriptase
activity was determined from the medium as a measure of virus replication.
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(RCMV1) and 68% (RCMV2) of the MLV-(MOA) control
(100%) (data not shown). These data demonstrate that
transcription of MLV-(RCMV) is controlled by a CMV IE
promoter/enhancer unit in the context of an enhancer-
deficient MLV LTR.
DISCUSSION
We have used an amphotropic murine leukemia virus
FIG. 5. RT-PCR analysis of MLV-(MOA) or MLV-(RCMV) from MCF-7
cells. RNA isolated from medium of uninfected MCF-7 cells (Mock),
MLV-(MOA)-infected MCF-7 cells (MOA), or MLV-(RCMV)-infected
MCF-7 cells was used to generate cDNA. This cDNA (virus) and
provirus expression plasmids (plasmid) were amplified by PCR with
primer FS1 and primer FS3 (specific for the MLV R region) or HR2
(specific for the MSV R region). The products were resolved on a 5%
PAA gel and visualized by silver staining. The approximate size of
identified fragments is indicated on the left, and the virus type defined
by this fragment is given on the right (MOA, DE, RCMV 1, and RCMV 2).
A schematic representation of MLV genomic RNA, indicating the R, U5,
and U3 regions and the relative position of primer binding sites is
depicted at the bottom.to study the replication of this virus in human cells and to
test the effect of MLV enhancers on viral gene expres-sion and replication. The virus generated and described
here, MLV-(MOA), is an amphotropic host range recom-
binant of Moloney murine leukemia virus. The data dem-
onstrate that this virus replicates in all human breast
carcinoma-derived cell lines tested. We show that re-
moval of the two 75-bp MLV enhancers abrogates or
drastically reduces the virus’s ability to replicate in all the
cell lines included in our study. However, replication
capacity can be restored in two of the six cell lines by
spontaneous recombinational insertion of the CMV ma-
jor IE gene promoter and enhancer, present on the viral
expression plasmid, into the U3 region. The newly se-
lected, recombinant virus was designated MLV-(RCMV)
and consists of a major population, RCMV 1, and a minor
population, RCMV 2, that differ in the length of the CMV
enhancer segment included. The recombination process
is likely to proceed via a transcript from the expression
plasmid that is initiated 59 of the provirus and includes
the CMV promoter, RNA packaging into virions, and the
generation of RCMV recombinants during reverse-tran-
scription. Infection studies with this virus show that it is
not the recombination process but the differential repli-
cation capacity of the resulting virus that restricts the
outgrowth of MLV-(RCMV) to specific cell lines. It is our
hypothesis that the newly generated, hybrid RCMV LTR
provides this cell type-specific transcriptional activity. As
part of a MLV-(RCMV) provirus the CMV IE promoter is
integrated into the host genome. In this context, the CMV
major IE promoter cannot be considered the broadly
active transcription element that is commonly used in
transient gene expression studies: In transgenic mice
this promoter exhibits a pronounced tissue preference
for retinal cells of the eye, ductile cells of the salivary
gland, exocrine cells of the pancreas, mucosal cells of
the stomach and intestine, neuronal cells of the brain,
muscle fibers, thecal cells of the corpus luteum, and
Leydig and sperm cells of the testis and breast tissue
(Baskar et al., 1996; Schmidt et al., 1990). Thus the se-
lective gene expression and replication of MLV-(RCMV),
due to the integrated state of the proviruses, may resem-
ble the patterns seen in transgenic mice. The presence
of truncated versions of the CMV IE promoter/enhancer
unit (positions 2458 to 21 and 2238 to 21) in RCMV
and the interaction of MLV and CMV transcription ele-
ments may provide further clues to the biological prop-
erties of MLV-(RCMV). The tissue specificity of MLV-
(RCMV) LTRs is currently tested in an MLV-derived vec-
tor. It is well documented that the tumors derived from
human breast tissue are very heterogeneous with re-
spect to treatment and expression of cellular markers
such as hormone receptors, keratins, and others (Clarke
et al., 1996; Rønnov-Jessen et al., 1996). The differential
replication of MLV-(RCMV) in these cell lines is likely
attributed to these differences. However, it is currently
not known what distinguishes the MLV-(RCMV)-permis-
sive cell lines MCF-7 and ZR-75-1 from the nonpermis-
leotide
98 REUSS ET AL.sive mammary cell lines and whether other human cell
types are also susceptible to these viruses.
The replication of MLV-(MOA) in mammary epithelial
cells depends on the presence of a functional promoter/
enhancer unit, of either MLV or heterologous origin, in
the viral U3 region. The spontaneous recombination and
insertion of the CMV promoter/enhancer unit into the
enhancer-deficient U3 region and the subsequent ampli-
fication of this virus illustrate the power of this selection
system in human cells. Similarly, during the production
process for MLV-based vectors, recombination between
vector and packaging components may generate repli-
cation-competent amphotropic MLV (Donahue et al.,
1992; Otto et al., 1994). Routine tests have been estab-
lished to detect such amphotropic MLV recombinants in
gene therapy vector preparations (U.S. Department of
Health and Human Services, 2000). The data presented
here demonstrate that MLV recombinants that carry CMV
IE transcription elements replacing the MLV U3 enhanc-
ers can arise and replicate in human cells. Current vec-
tor production procedures are designed to minimize re-
FIG. 6. DNA sequence of the U3-R region from the recombinant viru
of MLV-(RCMV) from infected MCF-7 cells were analyzed and the DN
immediate-early promoter and enhancer region (boxed), flanked by the
regular positions of the deleted MLV enhancer (DE) and the MLV and
by a dot, deletions are represented by a dash, and in the case of nuccombination and make the generation of replication-
competent MLV or MLV-(RCMV) unlikely. However, aresidual risk remains and in particular cases—such as
self-inactivating vectors that lack the viral transcription
elements but contain a CMV IE promoter—the potential
generation of MLV-(RCMV) must be considered.
MATERIALS AND METHODS
Plasmids and recombinant viral constructs
Plasmid pMLV-(MOA) contains an MLV provirus with
an amphotropic host range cloned into the NheI and
EcoRI sites of the plasmid pGEM-3 (Promega). The pro-
virus MLV-(MOA) was assembled from an XbaI/SpeI frag-
ment from pHIT110 (Soneoka et al., 1995) containing a
Moloney murine sarcoma virus (MSV) 59 LTR with the U3
region replaced by the CMV IE promoter/enhancer unit,
a SpeI/SalI fragment from p63-2 (Linney et al., 1984) with
gag and the 59 part of the pol gene, a SalI/NheI fragment
with the 39 portion of the pol gene and the amphotropic
env gene from pAMS (Miller et al., 1985), and a PCR-
generated NheI/EcoRI fragment with the MLV 39 LTR of
p63-2. In plasmid pMLV-(MOA)DE the 39 LTR of pMLV-
(RCMV). Three cDNA clones (Nos. 6, 15, 9) containing the U3-R region
uence was determined. The sequence alignment identifies the CMV
3 region (U3) and R region (R) on the 59 and 39 sides, respectively. The
TA-boxes (open rectangle) are shown. Sequence identity is indicated
exchanges the respective nucleotide is shown.s MLV-
A seq
MLV U
CMV TA(MOA) was replaced with the 39 LTR from pMLV/
CRBDMo (Linney et al., 1984).
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We have used the murine fibroblast line NIH/3T3 and
the human breast carcinoma-derived lines MCF-7, T47D,
MDA-MB-435S, BT-474, and ZR-75-1 (supplied by DKFZ
Tumorbank, Heidelberg, Germany). All cells were cul-
tured in Dulbecco’s modified Eagle’s medium supple-
mented with 10% fetal calf serum, penicillin (100 IU/ml),
and streptomycin (100 mg/ml). For transfection, between
1 3 105 and 2 3 105 cells were plated and grown for 24 h.
Recombinant viral plasmids were introduced using Lipo-
fectamine (Gibco BRL). After exposure of cells to the
Lipofectamine/DNA mixture for 4 h at 37°C the medium
was removed and fresh medium was added. When the
cultures reached confluence the medium was harvested
and the cells were diluted into fresh medium. Trans-
fected cells were passaged for up to 80 days and MLV
replication was monitored using a RNA-dependent DNA-
polymerase (RT) assay.
Infection of cells
Target cells (2 3 105) for infection were plated and
grown for 24 h. Virus-containing medium was filtered
through a 0.45-mm Millex filter unit (Millipore) and serial
dilutions of this medium were tested for RT activity. RT
activities were determined from the linear range of the
dilution curve. For infection the medium was replaced by
2 ml of fresh medium and virus-containing medium
equivalent to 5 3 104 cpm of RT activity was added. After
4 h of incubation the medium was replaced by fresh
medium.
RNA-dependent DNA-polymerase (RT) assay
Cell culture supernatants were harvested, and cellular
debris was removed by centrifugation at 5400 rpm (5000
g) for 10 min at 4°C in a Hereus Megafuge 1.0R centri-
fuge (Rotor BS4402/A) and stored at 270°C. Virions from
1-ml aliquots were pelleted by centrifugation at 75,000
rpm for 10 min at 4°C with a TLA-100.3 rotor in a TL-100
ultracentrifuge (Beckman Instruments). The pellet was
resuspended in 20 ml RT buffer [50 mM Tris–HCl, pH 8.3,
125 mM NaCl, 20 mM DTT, 0.58 mM MnCl2, 0.05% NP-40,
10 mM TTP, 0.1 mCi/ml a-35S-TTP or a-33P-TTP (NEN,
Boston), 10 mg/ml poly(rA), 5 mg/ml oligo(dT)12–18 and
incubated for 60 min at 37°C. The reaction was termi-
nated by the addition of 200 ml stop solution (15 mM
NaCl, 100 mg/ml BSA, 0.1% tetrasodium-pyrophosphate)
and 25 ml of 60% TCA, kept on ice for 15 min, and filtered
through HAWP02500 membranes (Millipore). Filters were
successively washed with 6% TCA and 70% ethanol and
dried at 80°C for 30 min. The TTP incorporation was
determined in a 1450 MicroBeta Trilux liquid scintillation
counter (Wallac Oy, Turku, Finland) for 1 min. Conditioned
medium from Abelson murine leukemia virus-infected
2M3/M cells was used as positive control (Rosenberg et
al., 1975).Extraction of viral RNA, RT-PCR analysis, and DNA
sequence determination
For isolation of viral RNA, cell culture supernatants
were cleared and virions were pelleted by ultracentrifu-
gation as described above. The virus-containing pellet
was resuspended in 1 ml buffer (0.15 M NaCl, 20 mM
Tris–HCl, pH 7.5, 5 mM EDTA, 100 mg yeast RNA/ml).
After addition of pronase and SDS to final concentrations
of 250 mg/ml and 1%, respectively, the sample was incu-
bated at 37°C for 30 min, extracted with phenol, and
precipitated with ethanol. The RNA was reverse-tran-
scribed using Superscript MLV reverse transcriptase
(Life Science/BRL). The cDNA was amplified using re-
combinant Pwo-DNA polymerase (Peqlab, Erlangen,
Germany) and primers FS1 (59 TGG CAA GCT AGC TTA
AGT 39) and FS3 (59 AAG CTT GCG GCC GCT GCA ACT
GCA AGA GGG TT 39) for the Mo-MLV R-region or HR2
(AAG CTT GCG GCC GCT GCA AAC AGC AAG AGG CTT)
for the Mo-MSV R-region. The PCR products were sep-
arated on a 5% nondenaturing PAA gel and visualized
through silver staining as described (Bassam et al.,
1991). For DNA sequence determination the PCR prod-
ucts were purified with the Qiaquick PCR purification kit
(Qiagen) and cloned into the vector pUC18. Sequence
analysis was done using the fluorescent dye terminator
method (ABI PRISM Big Dye Ready Reaction Terminator
Cycle Sequencing kit) on a Model 377 automated se-
quencer (Perkin–Elmer/Applied Biosystems).
Isolation of genomic DNA and Southern blot analysis
Cells were lysed in lysis buffer (50 mM Tris–HCl, pH
8.0, 10 mM EDTA, 0.5% SDS) and incubated with 20
mg/ml RNase A at 37°C for 1 h. The lysate was extracted
with phenol and chloroform:isoamylalcohol (24:1) and
ethanol precipitated. For Southern blot analysis, 12 mg
DNA was digested with a restriction enzyme, run on a
0.8% agarose gel, and transferred to a Hybond-N (Amer-
sham) membrane. Radiolabeled probes were generated
from isolated DNA fragments by random hexamer oligo-
nucleotide-primed synthesis with Klenow DNA polymer-
ase in the presence of a-32P-dCTP. Probe 1 corresponds
to a 1.8-kb HindIII fragment from position 452 in the
4070A integrase coding region (Ey et al., 1997) to position
1120 in the 4070A env gene (Ott et al., 1990). Probe 2
represents a BamHI/ClaI fragment from position 1219 to
1901 within the env gene (Ott et al., 1990). The CMV
promoter probe was isolated from plasmid pHIT110 as a
513-bp XbaI/SacI fragment (position 1 to 513) (Soneoka et
al., 1995). Hybridization was performed as described
(Church and Gilbert, 1984).
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